ReviewAmerican journal of hematology2012
Cancer and coagulation.
Review in American journal of hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 85 citations in OpenAlex.
- Thromboembolic disease in testicular germ cell tumors-real-world evidence of three Portuguese institutions.Frontiers in oncology · 2026Article
- Bridging via extracorporeal cardiopulmonary resuscitation for hemodynamic collapse in a patient with metastatic lung cancer: a case report.JA clinical reports · 2025Article
- Specific Cardiovascular Mortality in Cancer Survivors: A Nationwide Population-Based Cohort Study in Japan.Journal of the American Heart Association · 2025Article
- Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies.Current treatment options in oncology · 2024Review
- Clinical guidelines for prevention and treatment of CAT in Japan and other countries.International journal of hematology · 2024Review
- Article
- Smoking and Activated Clotting Time during coronary angiography and angioplasty: protocol for the ACT-Tobacco trial.Research and practice in thrombosis and haemostasis · 2023Article
- Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.Journal for immunotherapy of cancer · 2023Article
- Lung cancer presenting with acute myocardial infarction and pulmonary embolism within 1 month.SAGE open medical case reports · 2023Article
- The secret enemy during a flight: Economy class syndrome.Anatolian journal of cardiology · 2021Review
- The risk of venous thromboembolism in cancer patients receiving chemotherapy: a meta-analysis with systematic review.Annals of translational medicine · 2021Article
- Article
- Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma.Frontiers in medicine · 2021Review
- Review
- Risk factors for venous thromboembolism in endometrial cancer.Current oncology (Toronto, Ont.) · 2020Article
- Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study.Journal of thrombosis and haemostasis : JTH · 2020Article
- Prognostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Head and Neck Malignancies.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2020Article
- Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy.World journal of gastrointestinal oncology · 2020Review
- Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas.Cancers · 2020Review
- Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.Translational research : the journal of laboratory and clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Thromboembolism, including both venous and arterial events, occurs commonly amongst patients with cancer. The occurrence of thromboembolism has significant consequences for cancer patients, including direct and indirect associations with mortality, morbidity, requirement for long-term anticoagulant therapy and consumption of healthcare resources. Recent studies have resulted in a better understanding of clinical risk factors and biomarkers of cancer-associated thrombosis, and a risk assessment model incorporating both has now been validated in multiple settings. Thromboprophylaxis with either unfractionated heparin or low-molecular-weight heparins (LMWHs) has been shown to be safe and effective in high-risk settings such as hospitalization for medical illness and the postsurgical period. Emerging new data from randomized studies have focused on outpatient prophylaxis, suggesting potential benefits in this setting as well. Treatment of cancer-associated thrombosis requires long-term anticoagulation with LMWH. Results from ongoing and planned trials of novel anticoagulants in the cancer setting are awaited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.